ICU Medical Inc (ICUI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at ICU Medical Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 168.50 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -0.7% failed
- More than 10% revenue growth is expected for the coming year 4.5% failed
- Share count grows by less than 3% a year 1.4% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -2.3% failed
- Gross margin at 40% or higher and without meaningful erosion 36.8% failed
- Goodwill from acquisitions does not grow faster than revenue 37.0% failed
- Net debt below twice EBITDA 3.3 x EBITDA failed
- Operating cash flow covers the profits of the last three years 697 m passed
- Return on capital at 15% or higher, or up versus two years ago 3.0% passed
- Insiders hold at least 10% or are net buyers 3.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 4.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8.17 | 8.08 – 8.23 | 2,174 | 5.2% | 8 |
| 12/31/2027 | 9.34 | 9.10 – 9.65 | 2,272 | 14.3% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.49 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.97 | – | 630 | 7.10 | -3.80 | 40 | 14 |
| 2025: Q1 | -0.63 | – | 605 | 6.70 | -2.60 | 51 | 37 |
| 2025: Q2 | 1.43 | – | 549 | -8.00 | 6.40 | 11 | -11 |
| 2025: Q3 | -0.14 | – | 537 | -8.90 | -0.60 | 57 | 28 |
| 2025: Q4 | -0.64 | – | 540 | -14.20 | -2.90 | 61 | 36 |
| 2026: Q1 | 1.20 | – | 530 | -12.30 | 5.70 | 39 | 28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 379 | 83 | 63 | 3.66 | 90 | 660 | 705 |
| 2017 | 1,293 | -15 | 69 | 3.29 | 154 | 1,198 | 1,497 |
| 2018 | 1,400 | 22 | 29 | 1.33 | 160 | 1,264 | 1,585 |
| 2019 | 1,266 | 107 | 101 | 4.69 | 102 | 1,377 | 1,692 |
| 2020 | 1,271 | 98 | 87 | 4.02 | 223 | 1,502 | 1,764 |
| 2021 | 1,316 | 123 | 103 | 4.74 | 268 | 1,616 | 1,881 |
| 2022 | 2,280 | -43 | -74 | -3.11 | -62 | 2,090 | 4,516 |
| 2023 | 2,259 | 23 | -30 | -1.23 | 166 | 2,123 | 4,378 |
| 2024 | 2,382 | 43 | -118 | -4.83 | 204 | 1,965 | 4,204 |
| 2025 | 2,230 | 107 | 1 | 0.03 | 180 | 2,124 | 4,051 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 13,000 |
| Headquarters | San Clemente, CA |
| Address | 951 Calle Amanecer, 92673 San Clemente, United States |
| Phone | 949 366 2183 |
| Website | icumed.com |
| IPO Date | 31. Mar 1992 |
| ISIN | US44930G1076 |
| Stock Split | 3:2 on 03/18/2002 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Vivek Jain | CEO & Chairman of the Board | 1972 |
| Daniel Woolson | President | 1977 |
| Brian Michael Bonnell | CFO & Treasurer | 1974 |
| Christian B. Voigtlander | Chief Operating Officer | 1968 |
| Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 1975 |
| Ben Sousa | Chief Information Officer | – |
| Olivia Barrall | Vice President of Human Resources | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.